tetano
Editor, Senior Moderator
AMB Express. 2019 May 28;9(1):77. doi: 10.1186/s13568-019-0791-8.
[h=1]Evaluation of a novel micro/nanofluidic chip platform for the detection of influenza A and B virus in patients with influenza-like illness.[/h] Li R[SUP]1[/SUP], Gai W[SUP]2[/SUP], Zhu D[SUP]1[/SUP], Lok C[SUP]1[/SUP], Song C[SUP]2[/SUP], Dong J[SUP]1[/SUP], Han N[SUP]1[/SUP], Zhang Y[SUP]3[/SUP], Zhao X[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We introduced a novel micro/nanofluidic chip platform (MNCP), which is based on an isothermal nucleic acid amplification method. This study aimed to evaluate the MNCP method for influenza A and B viruses detecting and subtyping using throat swab samples from patients with influenza-like illness (ILI). A total of 266 throat swab samples from 266 non-repeated patients with ILI were tested for influenza A and B viruses using three methods, MNCP, a rapid influenza diagnostic test (RIDT), and real-time reverse transcription polymerase chain reaction (rRT-PCR). The results of MNCP were compared to those obtained by rRT-PCR and RIDT and the performance of MNCP was further evaluated. Compared with rRT-PCR results, the rates of sensitivity, specificity, overall concordance, and the kappa value of MNCP were 98.89%, 96.97%, 97.65%, and 0.95 for influenza A virus; 94.95%, 99.38%, 97.68%, and 0.95 for influenza B virus, respectively. Subtypes of influenza A viruses, e.g., A(H1N1)pdm09, A(H3N2), and A(not subtyped), and influenza B viruses could be distinguished in one MNCP assay within 1 h. Compared with rRT-PCR and MNCP, RIDT showed poor clinical sensitivity for influenza virus detection. This study showed MNCP is rapid, sensitive and versatile detecting system with potential for clinical application in pathogen diagnosis for patients with ILI.
[h=4]KEYWORDS:[/h] Influenza; Influenza-like illness; Nucleic acid sequence-based amplification; Rapid influenza diagnostic test
PMID: 31139958 DOI: 10.1186/s13568-019-0791-8
[h=1]Evaluation of a novel micro/nanofluidic chip platform for the detection of influenza A and B virus in patients with influenza-like illness.[/h] Li R[SUP]1[/SUP], Gai W[SUP]2[/SUP], Zhu D[SUP]1[/SUP], Lok C[SUP]1[/SUP], Song C[SUP]2[/SUP], Dong J[SUP]1[/SUP], Han N[SUP]1[/SUP], Zhang Y[SUP]3[/SUP], Zhao X[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We introduced a novel micro/nanofluidic chip platform (MNCP), which is based on an isothermal nucleic acid amplification method. This study aimed to evaluate the MNCP method for influenza A and B viruses detecting and subtyping using throat swab samples from patients with influenza-like illness (ILI). A total of 266 throat swab samples from 266 non-repeated patients with ILI were tested for influenza A and B viruses using three methods, MNCP, a rapid influenza diagnostic test (RIDT), and real-time reverse transcription polymerase chain reaction (rRT-PCR). The results of MNCP were compared to those obtained by rRT-PCR and RIDT and the performance of MNCP was further evaluated. Compared with rRT-PCR results, the rates of sensitivity, specificity, overall concordance, and the kappa value of MNCP were 98.89%, 96.97%, 97.65%, and 0.95 for influenza A virus; 94.95%, 99.38%, 97.68%, and 0.95 for influenza B virus, respectively. Subtypes of influenza A viruses, e.g., A(H1N1)pdm09, A(H3N2), and A(not subtyped), and influenza B viruses could be distinguished in one MNCP assay within 1 h. Compared with rRT-PCR and MNCP, RIDT showed poor clinical sensitivity for influenza virus detection. This study showed MNCP is rapid, sensitive and versatile detecting system with potential for clinical application in pathogen diagnosis for patients with ILI.
[h=4]KEYWORDS:[/h] Influenza; Influenza-like illness; Nucleic acid sequence-based amplification; Rapid influenza diagnostic test
PMID: 31139958 DOI: 10.1186/s13568-019-0791-8